Marvel Biosciences Corp. (MRVL.V)
| Previous Close | 0.1350 |
| Open | 0.1350 |
| Bid | 0.1300 x N/A |
| Ask | 0.1350 x N/A |
| Day's Range | 0.1350 - 0.1350 |
| 52 Week Range | 0.0100 - 0.1900 |
| Volume | |
| Avg. Volume | 46,157 |
| Market Cap | 5.371M |
| Beta (5Y Monthly) | 0.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0700 |
| Earnings Date | May 10, 2024 - May 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NewsfileMarvel Biosciences Announces Positive Interim Results on Tau Phosphorylation with MB-204
Calgary, Alberta--(Newsfile Corp. - March 25, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today reported promising interim results from its acute study on MB-204 conducted by Professor Emmanuel Planel of Laval University, a world expert on Tau pathology. Tau phosphorylation is a process where phosphates attach to a Tau protein in the brain. When Tau proteins become overly phosph
NewsfileMarvel Biosciences Announces Positive Interim Results for Autism Treatment with MB-204
Calgary, Alberta--(Newsfile Corp. - March 12, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today reported promising interim results from its study on MB-204, a new treatment for autism, conducted by the iBrain Institute in Tours, France. The study demonstrated that a single oral dose of MB-204 can restore social interaction behaviors to normal levels in autism model mice, with ..
NewsfileMarvel Biosciences Announces Testing MB-204 on Autism by French University
Calgary, Alberta--(Newsfile Corp. - February 20, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce it has begun testing MB-204 in the Oprm1 mouse model of autism in collaboration with Dr. Julie Le Merrer and Dr. Jerome Becker at the iBrain Institute, Tours, France."We are going to test the effect of acute dosing of MB-204 in one ...
